LianBio announces clinical supply agreement with AstraZeneca

LianBio (LIAN) announced a clinical supply agreement with AstraZeneca (AZN) in China to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor inhibitor, in a Phase 1 clinical study for the treatment of patients with non-small cell lung cancer with EGFR mutations. “In China, a disproportionately high percentage of NSCLC patients harbor EGFR mutations,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. “While EGFR inhibitors are a critical part of the standard of care, most patients eventually acquire resistance to these therapies. We believe BBP-398 is a differentiated SHP2 inhibitor with the potential to restore sensitivity to EGFR inhibitors when used in a combination setting.”